nodes	percent_of_prediction	percent_of_DWPC	metapath
Gliclazide—type 2 diabetes mellitus—atherosclerosis	0.467	1	CtDrD
Gliclazide—VEGFA—atherosclerosis	0.207	0.788	CbGaD
Gliclazide—ALB—atherosclerosis	0.0557	0.212	CbGaD
Gliclazide—ALB—Rosuvastatin—atherosclerosis	0.0307	0.206	CbGbCtD
Gliclazide—CYP2C19—Rosuvastatin—atherosclerosis	0.0199	0.133	CbGbCtD
Gliclazide—CYP2C19—Simvastatin—atherosclerosis	0.0185	0.124	CbGbCtD
Gliclazide—CYP2C19—Lovastatin—atherosclerosis	0.0181	0.121	CbGbCtD
Gliclazide—CYP2C9—Rosuvastatin—atherosclerosis	0.0165	0.111	CbGbCtD
Gliclazide—CYP2C9—Simvastatin—atherosclerosis	0.0154	0.103	CbGbCtD
Gliclazide—CYP2C9—Lovastatin—atherosclerosis	0.015	0.101	CbGbCtD
Gliclazide—CYP2C9—Pravastatin—atherosclerosis	0.015	0.101	CbGbCtD
Gliclazide—Glyburide—ABCA1—atherosclerosis	0.000568	0.536	CrCbGaD
Gliclazide—Glipizide—PPARG—atherosclerosis	0.000415	0.392	CrCbGaD
Gliclazide—Hypoaesthesia—Niacin—atherosclerosis	0.000143	0.00206	CcSEcCtD
Gliclazide—Erythema—Ezetimibe—atherosclerosis	0.000143	0.00205	CcSEcCtD
Gliclazide—Malnutrition—Ezetimibe—atherosclerosis	0.000143	0.00205	CcSEcCtD
Gliclazide—Rhinitis—Pravastatin—atherosclerosis	0.000142	0.00204	CcSEcCtD
Gliclazide—Oedema peripheral—Niacin—atherosclerosis	0.000142	0.00204	CcSEcCtD
Gliclazide—Hepatitis—Pravastatin—atherosclerosis	0.000142	0.00203	CcSEcCtD
Gliclazide—Confusional state—Rosuvastatin—atherosclerosis	0.000142	0.00203	CcSEcCtD
Gliclazide—Back pain—Lovastatin—atherosclerosis	0.000141	0.00203	CcSEcCtD
Gliclazide—Hypoaesthesia—Pravastatin—atherosclerosis	0.000141	0.00202	CcSEcCtD
Gliclazide—Flatulence—Ezetimibe—atherosclerosis	0.000141	0.00202	CcSEcCtD
Gliclazide—Pharyngitis—Pravastatin—atherosclerosis	0.000141	0.00202	CcSEcCtD
Gliclazide—Chills—Simvastatin—atherosclerosis	0.000141	0.00202	CcSEcCtD
Gliclazide—Infection—Rosuvastatin—atherosclerosis	0.000139	0.002	CcSEcCtD
Gliclazide—Visual impairment—Niacin—atherosclerosis	0.000139	0.00199	CcSEcCtD
Gliclazide—Back pain—Ezetimibe—atherosclerosis	0.000138	0.00199	CcSEcCtD
Gliclazide—Nervous system disorder—Rosuvastatin—atherosclerosis	0.000138	0.00198	CcSEcCtD
Gliclazide—Thrombocytopenia—Rosuvastatin—atherosclerosis	0.000137	0.00197	CcSEcCtD
Gliclazide—Mental disorder—Simvastatin—atherosclerosis	0.000137	0.00197	CcSEcCtD
Gliclazide—Tremor—Lovastatin—atherosclerosis	0.000137	0.00196	CcSEcCtD
Gliclazide—Visual impairment—Pravastatin—atherosclerosis	0.000136	0.00196	CcSEcCtD
Gliclazide—Erythema—Simvastatin—atherosclerosis	0.000136	0.00196	CcSEcCtD
Gliclazide—Ill-defined disorder—Lovastatin—atherosclerosis	0.000135	0.00194	CcSEcCtD
Gliclazide—Eye disorder—Niacin—atherosclerosis	0.000134	0.00193	CcSEcCtD
Gliclazide—Flatulence—Simvastatin—atherosclerosis	0.000134	0.00193	CcSEcCtD
Gliclazide—Tinnitus—Niacin—atherosclerosis	0.000134	0.00193	CcSEcCtD
Gliclazide—Erythema multiforme—Pravastatin—atherosclerosis	0.000134	0.00192	CcSEcCtD
Gliclazide—Flushing—Niacin—atherosclerosis	0.000133	0.00192	CcSEcCtD
Gliclazide—Angioedema—Lovastatin—atherosclerosis	0.000133	0.00191	CcSEcCtD
Gliclazide—Ill-defined disorder—Ezetimibe—atherosclerosis	0.000133	0.00191	CcSEcCtD
Gliclazide—Anaemia—Ezetimibe—atherosclerosis	0.000132	0.0019	CcSEcCtD
Gliclazide—Tinnitus—Pravastatin—atherosclerosis	0.000132	0.0019	CcSEcCtD
Gliclazide—Malaise—Lovastatin—atherosclerosis	0.000131	0.00189	CcSEcCtD
Gliclazide—Flushing—Pravastatin—atherosclerosis	0.000131	0.00189	CcSEcCtD
Gliclazide—Angioedema—Ezetimibe—atherosclerosis	0.000131	0.00188	CcSEcCtD
Gliclazide—Leukopenia—Lovastatin—atherosclerosis	0.00013	0.00187	CcSEcCtD
Gliclazide—Chills—Niacin—atherosclerosis	0.000129	0.00185	CcSEcCtD
Gliclazide—Malaise—Ezetimibe—atherosclerosis	0.000129	0.00185	CcSEcCtD
Gliclazide—Arrhythmia—Niacin—atherosclerosis	0.000128	0.00185	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.000128	0.00184	CcSEcCtD
Gliclazide—Tremor—Simvastatin—atherosclerosis	0.000128	0.00184	CcSEcCtD
Gliclazide—Chills—Pravastatin—atherosclerosis	0.000127	0.00183	CcSEcCtD
Gliclazide—Insomnia—Rosuvastatin—atherosclerosis	0.000127	0.00182	CcSEcCtD
Gliclazide—Ill-defined disorder—Simvastatin—atherosclerosis	0.000126	0.00182	CcSEcCtD
Gliclazide—Arrhythmia—Pravastatin—atherosclerosis	0.000126	0.00182	CcSEcCtD
Gliclazide—Palpitations—Ezetimibe—atherosclerosis	0.000126	0.00182	CcSEcCtD
Gliclazide—Paraesthesia—Rosuvastatin—atherosclerosis	0.000126	0.00181	CcSEcCtD
Gliclazide—Anaemia—Simvastatin—atherosclerosis	0.000126	0.00181	CcSEcCtD
Gliclazide—Malnutrition—Niacin—atherosclerosis	0.000125	0.0018	CcSEcCtD
Gliclazide—Erythema—Niacin—atherosclerosis	0.000125	0.0018	CcSEcCtD
Gliclazide—Cough—Ezetimibe—atherosclerosis	0.000125	0.00179	CcSEcCtD
Gliclazide—Angioedema—Simvastatin—atherosclerosis	0.000125	0.00179	CcSEcCtD
Gliclazide—Chest pain—Lovastatin—atherosclerosis	0.000124	0.00178	CcSEcCtD
Gliclazide—Myalgia—Lovastatin—atherosclerosis	0.000124	0.00178	CcSEcCtD
Gliclazide—Arthralgia—Lovastatin—atherosclerosis	0.000124	0.00178	CcSEcCtD
Gliclazide—Anxiety—Lovastatin—atherosclerosis	0.000124	0.00178	CcSEcCtD
Gliclazide—Dyspepsia—Rosuvastatin—atherosclerosis	0.000124	0.00178	CcSEcCtD
Gliclazide—Hypertension—Ezetimibe—atherosclerosis	0.000123	0.00177	CcSEcCtD
Gliclazide—Flatulence—Niacin—atherosclerosis	0.000123	0.00177	CcSEcCtD
Gliclazide—Malaise—Simvastatin—atherosclerosis	0.000123	0.00177	CcSEcCtD
Gliclazide—Tension—Niacin—atherosclerosis	0.000123	0.00176	CcSEcCtD
Gliclazide—Discomfort—Lovastatin—atherosclerosis	0.000123	0.00176	CcSEcCtD
Gliclazide—Leukopenia—Simvastatin—atherosclerosis	0.000122	0.00175	CcSEcCtD
Gliclazide—Chest pain—Ezetimibe—atherosclerosis	0.000122	0.00175	CcSEcCtD
Gliclazide—Arthralgia—Ezetimibe—atherosclerosis	0.000122	0.00175	CcSEcCtD
Gliclazide—Myalgia—Ezetimibe—atherosclerosis	0.000122	0.00175	CcSEcCtD
Gliclazide—Nervousness—Niacin—atherosclerosis	0.000122	0.00175	CcSEcCtD
Gliclazide—Flatulence—Pravastatin—atherosclerosis	0.000121	0.00174	CcSEcCtD
Gliclazide—Dry mouth—Lovastatin—atherosclerosis	0.000121	0.00174	CcSEcCtD
Gliclazide—Tension—Pravastatin—atherosclerosis	0.000121	0.00174	CcSEcCtD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.000121	0.00174	CcSEcCtD
Gliclazide—Discomfort—Ezetimibe—atherosclerosis	0.00012	0.00173	CcSEcCtD
Gliclazide—Pain—Rosuvastatin—atherosclerosis	0.00012	0.00172	CcSEcCtD
Gliclazide—Constipation—Rosuvastatin—atherosclerosis	0.00012	0.00172	CcSEcCtD
Gliclazide—Confusional state—Lovastatin—atherosclerosis	0.00012	0.00172	CcSEcCtD
Gliclazide—Nervousness—Pravastatin—atherosclerosis	0.00012	0.00172	CcSEcCtD
Gliclazide—Dry mouth—Ezetimibe—atherosclerosis	0.000119	0.00171	CcSEcCtD
Gliclazide—Infection—Lovastatin—atherosclerosis	0.000118	0.0017	CcSEcCtD
Gliclazide—Confusional state—Ezetimibe—atherosclerosis	0.000118	0.00169	CcSEcCtD
Gliclazide—Thrombocytopenia—Lovastatin—atherosclerosis	0.000116	0.00167	CcSEcCtD
Gliclazide—Arthralgia—Simvastatin—atherosclerosis	0.000116	0.00167	CcSEcCtD
Gliclazide—Chest pain—Simvastatin—atherosclerosis	0.000116	0.00167	CcSEcCtD
Gliclazide—Myalgia—Simvastatin—atherosclerosis	0.000116	0.00167	CcSEcCtD
Gliclazide—Infection—Ezetimibe—atherosclerosis	0.000116	0.00167	CcSEcCtD
Gliclazide—Feeling abnormal—Rosuvastatin—atherosclerosis	0.000116	0.00166	CcSEcCtD
Gliclazide—Anxiety—Simvastatin—atherosclerosis	0.000116	0.00166	CcSEcCtD
Gliclazide—Tremor—Pravastatin—atherosclerosis	0.000115	0.00166	CcSEcCtD
Gliclazide—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.000115	0.00165	CcSEcCtD
Gliclazide—Discomfort—Simvastatin—atherosclerosis	0.000115	0.00165	CcSEcCtD
Gliclazide—Nervous system disorder—Ezetimibe—atherosclerosis	0.000114	0.00164	CcSEcCtD
Gliclazide—Angioedema—Niacin—atherosclerosis	0.000114	0.00164	CcSEcCtD
Gliclazide—Ill-defined disorder—Pravastatin—atherosclerosis	0.000114	0.00164	CcSEcCtD
Gliclazide—Thrombocytopenia—Ezetimibe—atherosclerosis	0.000114	0.00164	CcSEcCtD
Gliclazide—Anaemia—Pravastatin—atherosclerosis	0.000114	0.00164	CcSEcCtD
Gliclazide—Skin disorder—Ezetimibe—atherosclerosis	0.000113	0.00163	CcSEcCtD
Gliclazide—Angioedema—Pravastatin—atherosclerosis	0.000113	0.00162	CcSEcCtD
Gliclazide—Confusional state—Simvastatin—atherosclerosis	0.000112	0.00161	CcSEcCtD
Gliclazide—Leukopenia—Niacin—atherosclerosis	0.000112	0.00161	CcSEcCtD
Gliclazide—Urticaria—Rosuvastatin—atherosclerosis	0.000112	0.0016	CcSEcCtD
Gliclazide—Malaise—Pravastatin—atherosclerosis	0.000111	0.0016	CcSEcCtD
Gliclazide—Abdominal pain—Rosuvastatin—atherosclerosis	0.000111	0.00159	CcSEcCtD
Gliclazide—Palpitations—Niacin—atherosclerosis	0.000111	0.00159	CcSEcCtD
Gliclazide—Infection—Simvastatin—atherosclerosis	0.000111	0.00159	CcSEcCtD
Gliclazide—Leukopenia—Pravastatin—atherosclerosis	0.00011	0.00159	CcSEcCtD
Gliclazide—Loss of consciousness—Niacin—atherosclerosis	0.00011	0.00158	CcSEcCtD
Gliclazide—Cough—Niacin—atherosclerosis	0.000109	0.00157	CcSEcCtD
Gliclazide—Thrombocytopenia—Simvastatin—atherosclerosis	0.000109	0.00157	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.000108	0.00156	CcSEcCtD
Gliclazide—Insomnia—Lovastatin—atherosclerosis	0.000108	0.00155	CcSEcCtD
Gliclazide—Cough—Pravastatin—atherosclerosis	0.000108	0.00155	CcSEcCtD
Gliclazide—Paraesthesia—Lovastatin—atherosclerosis	0.000107	0.00153	CcSEcCtD
Gliclazide—Arthralgia—Niacin—atherosclerosis	0.000107	0.00153	CcSEcCtD
Gliclazide—Myalgia—Niacin—atherosclerosis	0.000107	0.00153	CcSEcCtD
Gliclazide—Hypertension—Pravastatin—atherosclerosis	0.000106	0.00153	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.000106	0.00153	CcSEcCtD
Gliclazide—Dyspnoea—Lovastatin—atherosclerosis	0.000106	0.00152	CcSEcCtD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.000106	0.00152	CcSEcCtD
Gliclazide—Insomnia—Ezetimibe—atherosclerosis	0.000106	0.00152	CcSEcCtD
Gliclazide—Arthralgia—Pravastatin—atherosclerosis	0.000105	0.00151	CcSEcCtD
Gliclazide—Chest pain—Pravastatin—atherosclerosis	0.000105	0.00151	CcSEcCtD
Gliclazide—Myalgia—Pravastatin—atherosclerosis	0.000105	0.00151	CcSEcCtD
Gliclazide—Paraesthesia—Ezetimibe—atherosclerosis	0.000105	0.00151	CcSEcCtD
Gliclazide—Dyspepsia—Lovastatin—atherosclerosis	0.000105	0.0015	CcSEcCtD
Gliclazide—Anxiety—Pravastatin—atherosclerosis	0.000105	0.0015	CcSEcCtD
Gliclazide—Dry mouth—Niacin—atherosclerosis	0.000104	0.0015	CcSEcCtD
Gliclazide—Dyspnoea—Ezetimibe—atherosclerosis	0.000104	0.00149	CcSEcCtD
Gliclazide—Discomfort—Pravastatin—atherosclerosis	0.000104	0.00149	CcSEcCtD
Gliclazide—Hypersensitivity—Rosuvastatin—atherosclerosis	0.000103	0.00149	CcSEcCtD
Gliclazide—Dyspepsia—Ezetimibe—atherosclerosis	0.000103	0.00148	CcSEcCtD
Gliclazide—Fatigue—Lovastatin—atherosclerosis	0.000103	0.00147	CcSEcCtD
Gliclazide—Constipation—Lovastatin—atherosclerosis	0.000102	0.00146	CcSEcCtD
Gliclazide—Pain—Lovastatin—atherosclerosis	0.000102	0.00146	CcSEcCtD
Gliclazide—Confusional state—Pravastatin—atherosclerosis	0.000101	0.00146	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.000101	0.00146	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.000101	0.00145	CcSEcCtD
Gliclazide—Asthenia—Rosuvastatin—atherosclerosis	0.000101	0.00145	CcSEcCtD
Gliclazide—Insomnia—Simvastatin—atherosclerosis	0.000101	0.00145	CcSEcCtD
Gliclazide—Fatigue—Ezetimibe—atherosclerosis	0.000101	0.00145	CcSEcCtD
Gliclazide—Infection—Pravastatin—atherosclerosis	9.99e-05	0.00144	CcSEcCtD
Gliclazide—Paraesthesia—Simvastatin—atherosclerosis	9.99e-05	0.00144	CcSEcCtD
Gliclazide—Pain—Ezetimibe—atherosclerosis	9.98e-05	0.00143	CcSEcCtD
Gliclazide—Constipation—Ezetimibe—atherosclerosis	9.98e-05	0.00143	CcSEcCtD
Gliclazide—Tachycardia—Niacin—atherosclerosis	9.97e-05	0.00143	CcSEcCtD
Gliclazide—Pruritus—Rosuvastatin—atherosclerosis	9.93e-05	0.00143	CcSEcCtD
Gliclazide—Skin disorder—Niacin—atherosclerosis	9.92e-05	0.00143	CcSEcCtD
Gliclazide—Dyspnoea—Simvastatin—atherosclerosis	9.92e-05	0.00143	CcSEcCtD
Gliclazide—Hyperhidrosis—Niacin—atherosclerosis	9.88e-05	0.00142	CcSEcCtD
Gliclazide—Thrombocytopenia—Pravastatin—atherosclerosis	9.85e-05	0.00142	CcSEcCtD
Gliclazide—Feeling abnormal—Lovastatin—atherosclerosis	9.8e-05	0.00141	CcSEcCtD
Gliclazide—Dyspepsia—Simvastatin—atherosclerosis	9.79e-05	0.00141	CcSEcCtD
Gliclazide—Gastrointestinal pain—Lovastatin—atherosclerosis	9.73e-05	0.0014	CcSEcCtD
Gliclazide—Hyperhidrosis—Pravastatin—atherosclerosis	9.72e-05	0.0014	CcSEcCtD
Gliclazide—Feeling abnormal—Ezetimibe—atherosclerosis	9.61e-05	0.00138	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Simvastatin—atherosclerosis	9.61e-05	0.00138	CcSEcCtD
Gliclazide—Diarrhoea—Rosuvastatin—atherosclerosis	9.6e-05	0.00138	CcSEcCtD
Gliclazide—Fatigue—Simvastatin—atherosclerosis	9.59e-05	0.00138	CcSEcCtD
Gliclazide—Hypotension—Niacin—atherosclerosis	9.55e-05	0.00137	CcSEcCtD
Gliclazide—Gastrointestinal pain—Ezetimibe—atherosclerosis	9.54e-05	0.00137	CcSEcCtD
Gliclazide—Constipation—Simvastatin—atherosclerosis	9.52e-05	0.00137	CcSEcCtD
Gliclazide—Pain—Simvastatin—atherosclerosis	9.52e-05	0.00137	CcSEcCtD
Gliclazide—Urticaria—Lovastatin—atherosclerosis	9.45e-05	0.00136	CcSEcCtD
Gliclazide—Abdominal pain—Lovastatin—atherosclerosis	9.4e-05	0.00135	CcSEcCtD
Gliclazide—Body temperature increased—Lovastatin—atherosclerosis	9.4e-05	0.00135	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Niacin—atherosclerosis	9.31e-05	0.00134	CcSEcCtD
Gliclazide—Dizziness—Rosuvastatin—atherosclerosis	9.28e-05	0.00133	CcSEcCtD
Gliclazide—Urticaria—Ezetimibe—atherosclerosis	9.27e-05	0.00133	CcSEcCtD
Gliclazide—Insomnia—Niacin—atherosclerosis	9.24e-05	0.00133	CcSEcCtD
Gliclazide—Abdominal pain—Ezetimibe—atherosclerosis	9.22e-05	0.00133	CcSEcCtD
Gliclazide—Body temperature increased—Ezetimibe—atherosclerosis	9.22e-05	0.00133	CcSEcCtD
Gliclazide—Paraesthesia—Niacin—atherosclerosis	9.17e-05	0.00132	CcSEcCtD
Gliclazide—Feeling abnormal—Simvastatin—atherosclerosis	9.17e-05	0.00132	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Pravastatin—atherosclerosis	9.17e-05	0.00132	CcSEcCtD
Gliclazide—Dyspnoea—Niacin—atherosclerosis	9.11e-05	0.00131	CcSEcCtD
Gliclazide—Gastrointestinal pain—Simvastatin—atherosclerosis	9.1e-05	0.00131	CcSEcCtD
Gliclazide—Insomnia—Pravastatin—atherosclerosis	9.1e-05	0.00131	CcSEcCtD
Gliclazide—Somnolence—Niacin—atherosclerosis	9.08e-05	0.0013	CcSEcCtD
Gliclazide—Paraesthesia—Pravastatin—atherosclerosis	9.03e-05	0.0013	CcSEcCtD
Gliclazide—Dyspepsia—Niacin—atherosclerosis	8.99e-05	0.00129	CcSEcCtD
Gliclazide—Dyspnoea—Pravastatin—atherosclerosis	8.97e-05	0.00129	CcSEcCtD
Gliclazide—Dyspepsia—Pravastatin—atherosclerosis	8.86e-05	0.00127	CcSEcCtD
Gliclazide—Rash—Rosuvastatin—atherosclerosis	8.85e-05	0.00127	CcSEcCtD
Gliclazide—Dermatitis—Rosuvastatin—atherosclerosis	8.84e-05	0.00127	CcSEcCtD
Gliclazide—Urticaria—Simvastatin—atherosclerosis	8.84e-05	0.00127	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Niacin—atherosclerosis	8.82e-05	0.00127	CcSEcCtD
Gliclazide—Abdominal pain—Simvastatin—atherosclerosis	8.8e-05	0.00126	CcSEcCtD
Gliclazide—Body temperature increased—Simvastatin—atherosclerosis	8.8e-05	0.00126	CcSEcCtD
Gliclazide—Headache—Rosuvastatin—atherosclerosis	8.79e-05	0.00126	CcSEcCtD
Gliclazide—Hypersensitivity—Lovastatin—atherosclerosis	8.76e-05	0.00126	CcSEcCtD
Gliclazide—Pain—Niacin—atherosclerosis	8.74e-05	0.00126	CcSEcCtD
Gliclazide—Fatigue—Pravastatin—atherosclerosis	8.67e-05	0.00125	CcSEcCtD
Gliclazide—Pain—Pravastatin—atherosclerosis	8.6e-05	0.00124	CcSEcCtD
Gliclazide—Constipation—Pravastatin—atherosclerosis	8.6e-05	0.00124	CcSEcCtD
Gliclazide—Hypersensitivity—Ezetimibe—atherosclerosis	8.6e-05	0.00123	CcSEcCtD
Gliclazide—Asthenia—Lovastatin—atherosclerosis	8.54e-05	0.00123	CcSEcCtD
Gliclazide—Pruritus—Lovastatin—atherosclerosis	8.42e-05	0.00121	CcSEcCtD
Gliclazide—Asthenia—Ezetimibe—atherosclerosis	8.37e-05	0.0012	CcSEcCtD
Gliclazide—Gastrointestinal pain—Niacin—atherosclerosis	8.35e-05	0.0012	CcSEcCtD
Gliclazide—Nausea—Rosuvastatin—atherosclerosis	8.34e-05	0.0012	CcSEcCtD
Gliclazide—Feeling abnormal—Pravastatin—atherosclerosis	8.29e-05	0.00119	CcSEcCtD
Gliclazide—Pruritus—Ezetimibe—atherosclerosis	8.25e-05	0.00119	CcSEcCtD
Gliclazide—Gastrointestinal pain—Pravastatin—atherosclerosis	8.23e-05	0.00118	CcSEcCtD
Gliclazide—Hypersensitivity—Simvastatin—atherosclerosis	8.2e-05	0.00118	CcSEcCtD
Gliclazide—Diarrhoea—Lovastatin—atherosclerosis	8.14e-05	0.00117	CcSEcCtD
Gliclazide—Urticaria—Niacin—atherosclerosis	8.12e-05	0.00117	CcSEcCtD
Gliclazide—Abdominal pain—Niacin—atherosclerosis	8.08e-05	0.00116	CcSEcCtD
Gliclazide—Body temperature increased—Niacin—atherosclerosis	8.08e-05	0.00116	CcSEcCtD
Gliclazide—Urticaria—Pravastatin—atherosclerosis	7.99e-05	0.00115	CcSEcCtD
Gliclazide—Asthenia—Simvastatin—atherosclerosis	7.98e-05	0.00115	CcSEcCtD
Gliclazide—Diarrhoea—Ezetimibe—atherosclerosis	7.98e-05	0.00115	CcSEcCtD
Gliclazide—Abdominal pain—Pravastatin—atherosclerosis	7.95e-05	0.00114	CcSEcCtD
Gliclazide—Body temperature increased—Pravastatin—atherosclerosis	7.95e-05	0.00114	CcSEcCtD
Gliclazide—Pruritus—Simvastatin—atherosclerosis	7.87e-05	0.00113	CcSEcCtD
Gliclazide—Dizziness—Lovastatin—atherosclerosis	7.87e-05	0.00113	CcSEcCtD
Gliclazide—Dizziness—Ezetimibe—atherosclerosis	7.72e-05	0.00111	CcSEcCtD
Gliclazide—Glyburide—ALB—atherosclerosis	7.62e-05	0.072	CrCbGaD
Gliclazide—Diarrhoea—Simvastatin—atherosclerosis	7.61e-05	0.00109	CcSEcCtD
Gliclazide—Vomiting—Lovastatin—atherosclerosis	7.56e-05	0.00109	CcSEcCtD
Gliclazide—Hypersensitivity—Niacin—atherosclerosis	7.53e-05	0.00108	CcSEcCtD
Gliclazide—Rash—Lovastatin—atherosclerosis	7.5e-05	0.00108	CcSEcCtD
Gliclazide—Dermatitis—Lovastatin—atherosclerosis	7.49e-05	0.00108	CcSEcCtD
Gliclazide—Headache—Lovastatin—atherosclerosis	7.45e-05	0.00107	CcSEcCtD
Gliclazide—Vomiting—Ezetimibe—atherosclerosis	7.42e-05	0.00107	CcSEcCtD
Gliclazide—Hypersensitivity—Pravastatin—atherosclerosis	7.41e-05	0.00106	CcSEcCtD
Gliclazide—Dizziness—Simvastatin—atherosclerosis	7.36e-05	0.00106	CcSEcCtD
Gliclazide—Rash—Ezetimibe—atherosclerosis	7.36e-05	0.00106	CcSEcCtD
Gliclazide—Dermatitis—Ezetimibe—atherosclerosis	7.35e-05	0.00106	CcSEcCtD
Gliclazide—Asthenia—Niacin—atherosclerosis	7.33e-05	0.00105	CcSEcCtD
Gliclazide—Headache—Ezetimibe—atherosclerosis	7.31e-05	0.00105	CcSEcCtD
Gliclazide—Pruritus—Niacin—atherosclerosis	7.23e-05	0.00104	CcSEcCtD
Gliclazide—Asthenia—Pravastatin—atherosclerosis	7.22e-05	0.00104	CcSEcCtD
Gliclazide—Pruritus—Pravastatin—atherosclerosis	7.12e-05	0.00102	CcSEcCtD
Gliclazide—Vomiting—Simvastatin—atherosclerosis	7.07e-05	0.00102	CcSEcCtD
Gliclazide—Nausea—Lovastatin—atherosclerosis	7.07e-05	0.00102	CcSEcCtD
Gliclazide—Rash—Simvastatin—atherosclerosis	7.02e-05	0.00101	CcSEcCtD
Gliclazide—Dermatitis—Simvastatin—atherosclerosis	7.01e-05	0.00101	CcSEcCtD
Gliclazide—Diarrhoea—Niacin—atherosclerosis	6.99e-05	0.001	CcSEcCtD
Gliclazide—Headache—Simvastatin—atherosclerosis	6.97e-05	0.001	CcSEcCtD
Gliclazide—Nausea—Ezetimibe—atherosclerosis	6.93e-05	0.000996	CcSEcCtD
Gliclazide—Diarrhoea—Pravastatin—atherosclerosis	6.88e-05	0.000989	CcSEcCtD
Gliclazide—Dizziness—Niacin—atherosclerosis	6.76e-05	0.000971	CcSEcCtD
Gliclazide—Dizziness—Pravastatin—atherosclerosis	6.65e-05	0.000956	CcSEcCtD
Gliclazide—Nausea—Simvastatin—atherosclerosis	6.61e-05	0.00095	CcSEcCtD
Gliclazide—Vomiting—Niacin—atherosclerosis	6.5e-05	0.000933	CcSEcCtD
Gliclazide—Rash—Niacin—atherosclerosis	6.44e-05	0.000925	CcSEcCtD
Gliclazide—Dermatitis—Niacin—atherosclerosis	6.44e-05	0.000925	CcSEcCtD
Gliclazide—Headache—Niacin—atherosclerosis	6.4e-05	0.00092	CcSEcCtD
Gliclazide—Vomiting—Pravastatin—atherosclerosis	6.4e-05	0.000919	CcSEcCtD
Gliclazide—Rash—Pravastatin—atherosclerosis	6.34e-05	0.000911	CcSEcCtD
Gliclazide—Dermatitis—Pravastatin—atherosclerosis	6.34e-05	0.00091	CcSEcCtD
Gliclazide—Headache—Pravastatin—atherosclerosis	6.3e-05	0.000905	CcSEcCtD
Gliclazide—Nausea—Niacin—atherosclerosis	6.07e-05	0.000872	CcSEcCtD
Gliclazide—Nausea—Pravastatin—atherosclerosis	5.98e-05	0.000858	CcSEcCtD
Gliclazide—ABCC8—Metabolism—AGT—atherosclerosis	8.79e-06	0.000174	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—HMGCR—atherosclerosis	8.7e-06	0.000173	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—APOE—atherosclerosis	8.61e-06	0.000171	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—APOB—atherosclerosis	8.55e-06	0.00017	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—CAV1—atherosclerosis	8.53e-06	0.000169	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—AGT—atherosclerosis	8.52e-06	0.000169	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—APOA1—atherosclerosis	8.51e-06	0.000169	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—ABCA1—atherosclerosis	8.51e-06	0.000169	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—MMP3—atherosclerosis	8.5e-06	0.000169	CbGpPWpGaD
Gliclazide—ALB—Metabolism—LCAT—atherosclerosis	8.47e-06	0.000168	CbGpPWpGaD
Gliclazide—ALB—Metabolism—FABP4—atherosclerosis	8.47e-06	0.000168	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—IGF2—atherosclerosis	8.46e-06	0.000168	CbGpPWpGaD
Gliclazide—ALB—Transmembrane transport of small molecules—PLG—atherosclerosis	8.38e-06	0.000166	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—APOE—atherosclerosis	8.35e-06	0.000166	CbGpPWpGaD
Gliclazide—ALB—Metabolism—APOA4—atherosclerosis	8.32e-06	0.000165	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—CAV1—atherosclerosis	8.27e-06	0.000164	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—APOA1—atherosclerosis	8.25e-06	0.000164	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—APOB—atherosclerosis	8.22e-06	0.000163	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CYP7A1—atherosclerosis	8.17e-06	0.000162	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ABCG1—atherosclerosis	8.09e-06	0.00016	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—EDN1—atherosclerosis	8.09e-06	0.00016	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CCL5—atherosclerosis	8.02e-06	0.000159	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—PRKCG—atherosclerosis	7.94e-06	0.000157	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—LPL—atherosclerosis	7.85e-06	0.000156	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—APOB—atherosclerosis	7.79e-06	0.000154	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PIK3CG—atherosclerosis	7.77e-06	0.000154	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—CD36—atherosclerosis	7.76e-06	0.000154	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—ABCA1—atherosclerosis	7.76e-06	0.000154	CbGpPWpGaD
Gliclazide—ALB—Transmembrane transport of small molecules—HMOX1—atherosclerosis	7.73e-06	0.000153	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PRKCG—atherosclerosis	7.63e-06	0.000151	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—LCAT—atherosclerosis	7.61e-06	0.000151	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—FABP4—atherosclerosis	7.61e-06	0.000151	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CYP27A1—atherosclerosis	7.55e-06	0.00015	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PIK3CG—atherosclerosis	7.53e-06	0.000149	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PPARG—atherosclerosis	7.5e-06	0.000149	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—APOA4—atherosclerosis	7.47e-06	0.000148	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—LPL—atherosclerosis	7.44e-06	0.000147	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—SPP1—atherosclerosis	7.43e-06	0.000147	CbGpPWpGaD
Gliclazide—ALB—Transmembrane transport of small molecules—APOB—atherosclerosis	7.4e-06	0.000147	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—IL6—atherosclerosis	7.38e-06	0.000146	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ABCG1—atherosclerosis	7.38e-06	0.000146	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—INS—atherosclerosis	7.35e-06	0.000146	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CYP7A1—atherosclerosis	7.33e-06	0.000145	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PPARG—atherosclerosis	7.27e-06	0.000144	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—GPX1—atherosclerosis	7.25e-06	0.000144	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—VEGFA—atherosclerosis	7.17e-06	0.000142	CbGpPWpGaD
Gliclazide—ALB—Metabolism—ALOX15—atherosclerosis	7.16e-06	0.000142	CbGpPWpGaD
Gliclazide—ALB—Metabolism—APOA2—atherosclerosis	7.16e-06	0.000142	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PLA2G2A—atherosclerosis	7.16e-06	0.000142	CbGpPWpGaD
Gliclazide—ALB—Metabolism—ALOX5AP—atherosclerosis	7.16e-06	0.000142	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—PDGFB—atherosclerosis	7.16e-06	0.000142	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—INS—atherosclerosis	7.13e-06	0.000141	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—MMP1—atherosclerosis	7.07e-06	0.00014	CbGpPWpGaD
Gliclazide—ALB—Metabolism—ABCG5—atherosclerosis	7.07e-06	0.00014	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—CD36—atherosclerosis	7.06e-06	0.00014	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—APOB—atherosclerosis	6.99e-06	0.000139	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—FABP4—atherosclerosis	6.94e-06	0.000138	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—LCAT—atherosclerosis	6.94e-06	0.000138	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PDGFB—atherosclerosis	6.88e-06	0.000136	CbGpPWpGaD
Gliclazide—ALB—Metabolism—LPA—atherosclerosis	6.83e-06	0.000135	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—AKT1—atherosclerosis	6.81e-06	0.000135	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—APOA4—atherosclerosis	6.81e-06	0.000135	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—CAV1—atherosclerosis	6.78e-06	0.000135	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—MAPK3—atherosclerosis	6.78e-06	0.000134	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CYP27A1—atherosclerosis	6.78e-06	0.000134	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—APOA1—atherosclerosis	6.77e-06	0.000134	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—ALB—atherosclerosis	6.74e-06	0.000134	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—AGT—atherosclerosis	6.71e-06	0.000133	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CYP7A1—atherosclerosis	6.69e-06	0.000133	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—AKT1—atherosclerosis	6.68e-06	0.000132	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—LPL—atherosclerosis	6.67e-06	0.000132	CbGpPWpGaD
Gliclazide—ALB—Metabolism—BGN—atherosclerosis	6.62e-06	0.000131	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—TGFB1—atherosclerosis	6.58e-06	0.00013	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—APOE—atherosclerosis	6.58e-06	0.00013	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—LEP—atherosclerosis	6.58e-06	0.00013	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PPARA—atherosclerosis	6.57e-06	0.00013	CbGpPWpGaD
Gliclazide—ALB—Metabolism—APOA5—atherosclerosis	6.55e-06	0.00013	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—ALB—atherosclerosis	6.54e-06	0.00013	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CAV1—atherosclerosis	6.52e-06	0.000129	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—atherosclerosis	6.51e-06	0.000129	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—APOA1—atherosclerosis	6.5e-06	0.000129	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—F2—atherosclerosis	6.46e-06	0.000128	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—NOS3—atherosclerosis	6.45e-06	0.000128	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ALOX15—atherosclerosis	6.43e-06	0.000127	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—APOA2—atherosclerosis	6.43e-06	0.000127	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ALOX5AP—atherosclerosis	6.43e-06	0.000127	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PLA2G2A—atherosclerosis	6.43e-06	0.000127	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—NOS2—atherosclerosis	6.38e-06	0.000127	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—APOB—atherosclerosis	6.37e-06	0.000126	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—AGT—atherosclerosis	6.36e-06	0.000126	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ABCG5—atherosclerosis	6.35e-06	0.000126	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—CD36—atherosclerosis	6.34e-06	0.000126	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PLA2G1B—atherosclerosis	6.3e-06	0.000125	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—ESR1—atherosclerosis	6.28e-06	0.000125	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—NOS3—atherosclerosis	6.25e-06	0.000124	CbGpPWpGaD
Gliclazide—ALB—Transmembrane transport of small molecules—PPARA—atherosclerosis	6.24e-06	0.000124	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—APOE—atherosclerosis	6.23e-06	0.000124	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—F2—atherosclerosis	6.2e-06	0.000123	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CYP27A1—atherosclerosis	6.18e-06	0.000123	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—PIK3CG—atherosclerosis	6.18e-06	0.000123	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—CAV1—atherosclerosis	6.17e-06	0.000122	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—APOA1—atherosclerosis	6.16e-06	0.000122	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—LPA—atherosclerosis	6.13e-06	0.000122	CbGpPWpGaD
Gliclazide—ALB—Metabolism—ALOX5—atherosclerosis	6.09e-06	0.000121	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—LPL—atherosclerosis	6.09e-06	0.000121	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—BGN—atherosclerosis	5.94e-06	0.000118	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—atherosclerosis	5.94e-06	0.000118	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PIK3CG—atherosclerosis	5.94e-06	0.000118	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PTGS2—atherosclerosis	5.9e-06	0.000117	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PPARA—atherosclerosis	5.9e-06	0.000117	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—APOA5—atherosclerosis	5.88e-06	0.000117	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ALOX15—atherosclerosis	5.86e-06	0.000116	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ALOX5AP—atherosclerosis	5.86e-06	0.000116	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PLA2G2A—atherosclerosis	5.86e-06	0.000116	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—APOA2—atherosclerosis	5.86e-06	0.000116	CbGpPWpGaD
Gliclazide—ALB—Transmembrane transport of small molecules—APOA1—atherosclerosis	5.86e-06	0.000116	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ABCG5—atherosclerosis	5.79e-06	0.000115	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—CD36—atherosclerosis	5.78e-06	0.000115	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PTGS2—atherosclerosis	5.72e-06	0.000113	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—AGT—atherosclerosis	5.71e-06	0.000113	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PLA2G1B—atherosclerosis	5.66e-06	0.000112	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—IGF1—atherosclerosis	5.66e-06	0.000112	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PIK3CG—atherosclerosis	5.62e-06	0.000112	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—INS—atherosclerosis	5.62e-06	0.000111	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—APOE—atherosclerosis	5.59e-06	0.000111	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—LPA—atherosclerosis	5.59e-06	0.000111	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—CAV1—atherosclerosis	5.54e-06	0.00011	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—APOA1—atherosclerosis	5.53e-06	0.00011	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CCL2—atherosclerosis	5.53e-06	0.00011	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ALOX5—atherosclerosis	5.47e-06	0.000108	CbGpPWpGaD
Gliclazide—ALB—Metabolism—NAMPT—atherosclerosis	5.46e-06	0.000108	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—IGF1—atherosclerosis	5.43e-06	0.000108	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PPARG—atherosclerosis	5.43e-06	0.000108	CbGpPWpGaD
Gliclazide—ALB—Metabolism—LIPC—atherosclerosis	5.43e-06	0.000108	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—BGN—atherosclerosis	5.41e-06	0.000107	CbGpPWpGaD
Gliclazide—ALB—Metabolism—APOC3—atherosclerosis	5.39e-06	0.000107	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PPARA—atherosclerosis	5.38e-06	0.000107	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—SERPINE1—atherosclerosis	5.37e-06	0.000107	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—APOA5—atherosclerosis	5.36e-06	0.000106	CbGpPWpGaD
Gliclazide—ALB—Metabolism—LDLR—atherosclerosis	5.36e-06	0.000106	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CETP—atherosclerosis	5.24e-06	0.000104	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—AGT—atherosclerosis	5.21e-06	0.000103	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—SERPINE1—atherosclerosis	5.16e-06	0.000102	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PLA2G1B—atherosclerosis	5.16e-06	0.000102	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—NOS3—atherosclerosis	5.13e-06	0.000102	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—APOE—atherosclerosis	5.1e-06	0.000101	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—atherosclerosis	5.05e-06	0.0001	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—atherosclerosis	5.05e-06	0.0001	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—APOA1—atherosclerosis	5.04e-06	0.0001	CbGpPWpGaD
Gliclazide—ALB—Metabolism—SCARB1—atherosclerosis	5.01e-06	9.94e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ALOX5—atherosclerosis	4.98e-06	9.88e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—NOS3—atherosclerosis	4.93e-06	9.77e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—NAMPT—atherosclerosis	4.9e-06	9.72e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—atherosclerosis	4.87e-06	9.66e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—LIPC—atherosclerosis	4.87e-06	9.66e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—APOC3—atherosclerosis	4.84e-06	9.6e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—LDLR—atherosclerosis	4.81e-06	9.54e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—HMGCR—atherosclerosis	4.73e-06	9.39e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CETP—atherosclerosis	4.7e-06	9.32e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—atherosclerosis	4.6e-06	9.13e-05	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—AKT1—atherosclerosis	4.57e-06	9.07e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—SCARB1—atherosclerosis	4.5e-06	8.93e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—NAMPT—atherosclerosis	4.47e-06	8.86e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—atherosclerosis	4.44e-06	8.81e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—LIPC—atherosclerosis	4.44e-06	8.81e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—APOC3—atherosclerosis	4.41e-06	8.75e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—LDLR—atherosclerosis	4.39e-06	8.7e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—ALB—atherosclerosis	4.38e-06	8.69e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CXCL8—atherosclerosis	4.37e-06	8.67e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CETP—atherosclerosis	4.29e-06	8.5e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	4.27e-06	8.47e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—HMGCR—atherosclerosis	4.25e-06	8.43e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—ABCA1—atherosclerosis	4.22e-06	8.37e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—SCARB1—atherosclerosis	4.1e-06	8.14e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—ALB—atherosclerosis	4e-06	7.92e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—MMP9—atherosclerosis	3.95e-06	7.84e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—NFKB1—atherosclerosis	3.91e-06	7.76e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—HMGCR—atherosclerosis	3.88e-06	7.69e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—MAPK8—atherosclerosis	3.84e-06	7.62e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	3.83e-06	7.6e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ABCA1—atherosclerosis	3.79e-06	7.51e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—VEGFA—atherosclerosis	3.69e-06	7.33e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—HMOX1—atherosclerosis	3.62e-06	7.18e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—STAT3—atherosclerosis	3.51e-06	6.97e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	3.5e-06	6.93e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—MAPK3—atherosclerosis	3.5e-06	6.93e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—APOB—atherosclerosis	3.47e-06	6.88e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ABCA1—atherosclerosis	3.45e-06	6.85e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—TGFB1—atherosclerosis	3.39e-06	6.73e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—GSTM1—atherosclerosis	3.37e-06	6.69e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—MAPK3—atherosclerosis	3.36e-06	6.66e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—LPL—atherosclerosis	3.31e-06	6.57e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—TGFB1—atherosclerosis	3.26e-06	6.46e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—HMOX1—atherosclerosis	3.25e-06	6.45e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—GPX1—atherosclerosis	3.23e-06	6.41e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CD36—atherosclerosis	3.15e-06	6.24e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—APOB—atherosclerosis	3.11e-06	6.17e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—GSTM1—atherosclerosis	3.03e-06	6.01e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—MTHFR—atherosclerosis	2.98e-06	5.91e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—LPL—atherosclerosis	2.97e-06	5.9e-05	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—AKT1—atherosclerosis	2.96e-06	5.88e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—HMOX1—atherosclerosis	2.96e-06	5.88e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PPARA—atherosclerosis	2.92e-06	5.8e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—GPX1—atherosclerosis	2.9e-06	5.75e-05	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—AKT1—atherosclerosis	2.87e-06	5.7e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—APOB—atherosclerosis	2.84e-06	5.63e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—AGT—atherosclerosis	2.83e-06	5.62e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CD36—atherosclerosis	2.82e-06	5.6e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—APOE—atherosclerosis	2.78e-06	5.5e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GSTM1—atherosclerosis	2.76e-06	5.48e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CAV1—atherosclerosis	2.75e-06	5.45e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—APOA1—atherosclerosis	2.74e-06	5.44e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—LPL—atherosclerosis	2.71e-06	5.38e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—MTHFR—atherosclerosis	2.68e-06	5.31e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GPX1—atherosclerosis	2.64e-06	5.24e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PPARA—atherosclerosis	2.63e-06	5.21e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CD36—atherosclerosis	2.58e-06	5.11e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—AGT—atherosclerosis	2.54e-06	5.04e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PIK3CG—atherosclerosis	2.5e-06	4.97e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—APOE—atherosclerosis	2.49e-06	4.94e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CAV1—atherosclerosis	2.47e-06	4.9e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—APOA1—atherosclerosis	2.46e-06	4.88e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—IL6—atherosclerosis	2.45e-06	4.87e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—MTHFR—atherosclerosis	2.44e-06	4.84e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PPARG—atherosclerosis	2.42e-06	4.79e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PPARA—atherosclerosis	2.39e-06	4.75e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—INS—atherosclerosis	2.37e-06	4.7e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—AKT1—atherosclerosis	2.36e-06	4.68e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—AGT—atherosclerosis	2.32e-06	4.6e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—APOE—atherosclerosis	2.27e-06	4.51e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—AKT1—atherosclerosis	2.26e-06	4.49e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CAV1—atherosclerosis	2.25e-06	4.46e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PIK3CG—atherosclerosis	2.25e-06	4.46e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—APOA1—atherosclerosis	2.25e-06	4.45e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PPARG—atherosclerosis	2.17e-06	4.3e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—INS—atherosclerosis	2.13e-06	4.22e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—NOS3—atherosclerosis	2.08e-06	4.12e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PIK3CG—atherosclerosis	2.05e-06	4.07e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PPARG—atherosclerosis	1.98e-06	3.92e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ALB—atherosclerosis	1.95e-06	3.87e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—INS—atherosclerosis	1.94e-06	3.85e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PTGS2—atherosclerosis	1.9e-06	3.77e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—NOS3—atherosclerosis	1.87e-06	3.7e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ALB—atherosclerosis	1.78e-06	3.53e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PTGS2—atherosclerosis	1.71e-06	3.39e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—NOS3—atherosclerosis	1.7e-06	3.38e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PTGS2—atherosclerosis	1.56e-06	3.09e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—AKT1—atherosclerosis	9.56e-07	1.9e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—AKT1—atherosclerosis	8.58e-07	1.7e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—AKT1—atherosclerosis	7.82e-07	1.55e-05	CbGpPWpGaD
